Livagen is a synthetic peptide of four amino acids, a tetrapeptide, and one of a group of short peptides that Vladimir Khavinson's laboratory built from peptide complexes extracted from organ tissue [1]. The liver complex supplied its template, and in organ culture the peptide stimulated liver explants rather than brain or thymus tissue [1]. It has no single parent protein in the sources reviewed, because the template was a tissue extract rather than one purified protein. Its family is the ultrashort peptide bioregulators, which a 2023 docking study from the same institute defines as two to eight amino acids [2].
Vladimir Khavinson's laboratory at the St. Petersburg Institute of Bioregulation and Gerontology in Russia reported Livagen as one of four organ-matched synthetic short peptides in a 2001 paper [1]. The paper called the group cytogens, synthetic peptides built using cytomedins, the peptide complexes extracted from tissues, and reported that each stimulated growth of explants from its matching organ [1]. Livagen was the liver member, and tissue specificity was the stated point of the design [1]. A 2002 study from the same network repeated the pattern across rats of different ages [3].
The research potential is epigenetic and hepatic: reactivating genes that age-related chromatin condensation has silenced, and supporting liver cell function in culture [4][5][6]. Epigenetic means a change in gene activity that does not alter the DNA sequence, and the chromatin papers treat dense chromatin as the physical form of that silencing. Both lines are laboratory findings in cultured lymphocytes and cultured liver tissue. As of October 2026, Livagen is not approved for human therapeutic use and no clinical trial of it is registered on ClinicalTrials.gov. Its regulatory position comes from catch-all language rather than from its name: WADA's S0 class covers substances with no current approval by any governmental regulatory health authority for human therapeutic use, and the NCAA peptide-hormone class covers chemically or pharmacologically related substances [7][8].
Key takeaways
- Livagen is a synthetic four-amino-acid peptide, the liver member of a set of short organ-matched peptides that Khavinson's laboratory reported in 2001 [1].
- In cultured human lymphocytes from older donors it decondensed heterochromatin and raised ribosomal gene activity, the findings behind its reputation as a chromatin-acting peptide [4][6][9].
- No clinical trial of it has been published or registered, and neither the WADA nor the NCAA list names it, so the catch-all language in both codes is what applies [7][8].
How it works
Chromatin remodeling and ribosomal gene activation
Livagen's most reproducible laboratory effect is on chromatin, the packaged form of DNA in the nucleus. DNA winds around histone proteins into units called nucleosomes, and tightly packed stretches called heterochromatin keep the genes inside them switched off. Ribosomal genes, the DNA instructions for the RNA component of the ribosome, sit in dense clusters called nucleolar organizer regions on the short arms of five acrocentric chromosome pairs. In aging lymphocytes heterochromatin accumulates, and the Livagen papers set out to see whether the peptide can loosen it [6][10].
The assays combined cytogenetics and calorimetry: differential scanning calorimetry, which measures the heat needed to melt chromatin and so reports how tightly it is packed; scoring of ribosomal gene activity at nucleolar organizer regions; mapping of constitutive heterochromatin, the permanent form, on chromosomes 1, 9 and 16; and counts of sister chromatid exchange [4][6][9]. Sister chromatids are the two identical copies of a chromosome made before cell division, and an exchange is a swap of DNA between them, which becomes more frequent when chromatin is open.
In lymphocytes from donors aged 75 to 88, Livagen raised ribosomal gene activity, decondensed the pericentromeric heterochromatin of chromosomes 1 and 9, and opened facultative heterochromatin, the conditional form that can silence genes [6][9]. Pericentromeric means the region flanking the centromere, the chromosome's attachment point for the spindle that pulls it apart during division. The authors interpret the decondensation as release of genes that age had repressed; the main readouts are chromosome structure and ribosomal gene activity rather than the expression of a named protein-coding gene [4]. The effect is selective: in the 2020 comparison of four peptides, each opened a different set of chromosome regions [6].
Enkephalin-degrading enzymes in blood serum
A second line of work puts Livagen in contact with the enkephalins, short opioid peptides that the body makes and then breaks down. Enkephalin-degrading enzymes, or enkephalinases, are peptidases in blood that cleave these peptides and end their signal. A molecule that inhibits those enzymes would prolong the enkephalin signal without docking at an opioid receptor, which is a different route into the same system [11].
Kost and colleagues measured the hydrolysis of tritiated, or radioactively labeled, leucine-enkephalin in human serum after adding Livagen or Epitalon [11]. Both peptides inhibited the serum enzymes, and Livagen was stronger, with a half-maximal inhibitory concentration, or IC50, of 20 micromolar against 500 micromolar for Epitalon [11]. Livagen also outperformed three known peptidase inhibitors, puromycin, leupeptin and D-PAM [11]. A radioreceptor assay, a binding test that uses a labeled ligand, showed no binding of either peptide to mu or delta opioid receptors in rat brain membranes [11].
The experiment ran in human serum outside the body, so it shows an enzyme interaction rather than an effect on opioid signaling in a living animal [11]. The abstract does not identify which of the serum peptidases Livagen inhibits. Twenty micromolar is a laboratory concentration, which leaves open whether a comparable tissue level is reachable.
Tissue specificity and the liver
The founding claim of the literature is tissue specificity: each short peptide was reported to act on the organ whose extract supplied its template. An explant is a small piece of tissue kept alive in culture, and an organotypic culture preserves something of the tissue's architecture instead of flattening it into a single layer of cells [1][3].
In the 2001 report, Livagen stimulated growth of rat liver explants, Cortagen did the same for brain cortex, Epithalon for subcortical structures and Vilon for thymus [1]. A 2002 follow-up tested the peptides against explants from cortex, subcortical structures, liver and thymus across rat ages and again reported tissue-specific effects at the concentrations used [3]. A separate 2002 study of organotypic liver culture found that Livagen stabilized the cell population and supported cellular and intracellular regeneration by morphological and antibody-based staining measures [5].
Tissue specificity here is a preference in one culture system. The abstracts do not identify a receptor or a transport route that would explain why liver tissue responds preferentially, and none reports how much peptide enters the cells. That gap leaves the mechanism open [1][5].
Transport modeling and stability
For a peptide to act inside a cell it has to cross the membrane, and Livagen's route has been modeled rather than measured. LAT1 and LAT2 are amino-acid transporters, membrane proteins that carry neutral amino acids into cells, and PEPT1 is a peptide transporter that carries di- and tripeptides. A 2023 docking study built structural models of 26 bioactive ultrashort peptides and scored how well each fits the binding sites of these transporters [2].
In the published tables, Livagen scored -28.83 at LAT1, ranking 11th of the 26 peptides, and -21.45 at LAT2, ranking 17th, where the authors name it among peptides likely to inhibit the transporter more strongly than known inhibitors [2]. At PEPT1 its score of -16.70 ranked 20th, within the range calculated for known inhibitors, while its PEPT2 score of 11.60 ranked 21st, at the weak end of the table [2]. Docking is a computer prediction of binding geometry and energy; it does not show that a peptide is carried across a membrane [2].
The one experimental stability result stands apart from the docking. Small-intestine peptide hydrolases did not break Livagen down to any appreciable extent in vitro, and the peptide reduced small-intestine dipeptidase activity by about 50 percent in the same experiments [12]. The authors describe the peptide as weakly hydrolyzed [12].
What has been studied in humans
As of October 2026, no clinical trial of Livagen has been published or registered, so the human evidence comes from cells and serum studied in the laboratory. A ClinicalTrials.gov search on October 23, 2026 returned no study for Livagen. The published human material comes from lymphocytes and serum studied in the laboratory: white blood cells from donors of known age, cultured in a dish and then examined for chromosome structure and gene activity [4][6][9].
The core studies drew lymphocytes from donors aged 75 to 88, and the 2020 comparison added a younger group aged 20 to 40 [6][9]. In the older group chromatin was more condensed, the change the authors describe as progressive heterochromatinization with age [6][10]. Livagen shifted part of that pattern in culture: ribosomal gene activity rose, pericentromeric heterochromatin on chromosomes 1 and 9 opened, and facultative heterochromatin decondensed [6][9]. The readouts were the melting profile of heterochromatin, ribosomal gene activity at nucleolar organizer regions, C-segment polymorphism (variation in the size of the stained heterochromatin block), and sister chromatid exchange counts [6][9].
Other studies widened the donor pool rather than the endpoint. Lymphocytes from patients with ductal breast cancer showed a high density of DNA single-strand breaks, a high frequency of chromosomal abnormalities and increased chromatin condensation, and Livagen with cobalt ions improved all the studied parameters [14]. Lymphocytes from donors aged 72 to 86 mounted a radiation adaptive response, the priming effect in which a low dose of radiation makes cells more resistant to a later larger dose, and Livagen modified that response [13]. Human serum supplied the enzyme source for the enkephalinase experiments, which found inhibition at 20 micromolar [11].
None of these experiments gave Livagen to a living human. The cells were cultured outside the body, the peptide was added to the culture medium, and the cell papers report chromosome structure rather than clinical outcomes [4][9]. That design can show that a peptide changes chromatin in human cells; it cannot show absorption, distribution, duration of effect or safety in a human.
Lab and animal studies
Preclinical means work in cells, tissue or animals before a treatment reaches human testing. For Livagen that work falls into three groups: chromatin and chromosome studies in cultured lymphocytes, liver and digestive-tissue studies, and enzyme or transport experiments [4][5][11].
The liver results are morphological. Organotypic culture keeps pieces of liver in a three-dimensional arrangement, and Livagen-treated cultures showed more stable cell populations and stronger cellular and intracellular regeneration on antibody-based (immunocytochemical) and morphometric analysis [5]. Explants from rat liver grew more in the presence of the peptide, the founding tissue-specific result [1]. A 2002 comparison across rat ages repeated the tissue-specific pattern for the whole peptide set, with Livagen matched to liver [3]. These are growth and structure endpoints, and the abstracts do not report a biochemical liver function measure.
The whole-animal work is one oral study. Rats received Livagen by mouth for two weeks, and digestive enzyme activity in the small intestine and in non-digestive organs fell in young animals while it rose in old animals, in most cases to the level of young controls [12]. The same paper found that small-intestine hydrolases did not cleave the peptide and that it cut dipeptidase activity by about 50 percent in vitro [12]. The age-dependent direction of the enzyme change is the notable part, because one peptide moved the same measure in opposite directions depending on the animal's age.
Beyond rat tissue, a 2007 Parkinsonism & Related Disorders item described a fruit-fly model of neurodegeneration, using heat shock in mutants of the kynurenine pathway, for the therapeutic activity of Cortagen and Livagen [16]. The Crossref record carries a title, author list and citation details but no abstract or results, so it shows the peptide was tested in another organism and adds no usable outcome.
The transport work is computational. Docking placed Livagen in the range of known inhibitors at LAT1, LAT2 and PEPT1, while its PEPT2 score sat at the weak end of the table and the authors said the PEPT2 data do not allow a reliable assessment [2]. Docking predicts binding geometry and energy, and it does not measure transport. The 2005 hydrolysis result is the clearest experimental support in the sources reviewed for the idea that the peptide survives long enough to be absorbed [12].
Several limits run through the whole set. Group sizes, peptide concentrations and effect sizes are often missing from the abstracts, many of the papers come from a small group of institutions in St. Petersburg and Tbilisi, and the chromatin findings rest on chromosome structure and ribosomal gene activity rather than on the expression of specific genes. For a synthetic tetrapeptide, identity and purity testing is part of the evidence picture; the COA library covers the tests.
Research in detail
Organotypic explant culture with four synthetic peptides tested in parallel · Explants of rat brain cortex, subcortical structures, liver and thymus
Each peptide stimulated growth of explants from the tissue whose peptide complex supplied its template; Livagen matched liver.
Evidence scope: Abstract only; the abstract gives no peptide concentrations, effect sizes or statistics, and it does not show that the effect is specific to one cell type within the explant.
Ex vivo lymphocyte culture with cytogenetic and calorimetric assays · Lymphocytes from older donors
Livagen activated ribosomal genes, decondensed pericentromeric structural heterochromatin and released genes repressed by age-related chromatin condensation.
Evidence scope: Abstract only; donor number, ages, peptide concentration and effect sizes are not in the abstract.
Organotypic liver culture with immunocytochemical and morphometric analysis · Cultured liver tissue
Livagen stabilized cell populations and strengthened cellular and intracellular regeneration.
Evidence scope: Abstract only; species, dose and quantitative morphometry are not reported, and the abstract reports morphological and immunocytochemical findings rather than a functional liver assay.
Organotypic explant culture comparing tissue extracts and short peptides · Explants of cortex, subcortical structures, liver and thymus from rats of different ages
The peptides, including Livagen, produced tissue-specific effects at the concentrations tested.
Evidence scope: Abstract only; no data by age or concentration appear, and the result is a growth effect in culture.
In vitro enzyme kinetics with tritiated leucine-enkephalin in human serum, plus a radioreceptor binding assay · Human serum and a rat brain membrane fraction
Livagen inhibited serum enkephalin-degrading enzymes with an IC50 of 20 micromolar, compared with 500 micromolar for Epitalon and more strongly than puromycin, leupeptin and D-PAM; neither peptide bound mu or delta opioid receptors.
Evidence scope: Abstract only; the assay is in vitro, the abstract does not identify the inhibited peptidase, and serum enzyme activity does not show an effect on opioid signaling in a living animal.
Ex vivo comparison of five short peptides in cultured leukocytes · Leukocytes from donors aged 75 to 88
All five peptides activated ribosomal genes and decondensed densely packed chromatin; Livagen and Epithalon also decondensed chromosome 1 and 9 pericentromeric heterochromatin.
Evidence scope: Abstract only; no effect sizes or peptide concentrations are given, and the readouts are chromosome morphology.
In vitro hydrolysis assay plus two weeks of oral administration in rats of different ages · Young and old rats, small intestine and non-digestive organs
Intestinal hydrolases did not cleave Livagen; it reduced small-intestine dipeptidase activity by 50 percent in vitro, and after oral dosing enzyme activity fell in young rats and rose in old rats toward young control levels.
Evidence scope: Abstract only; enzyme activity is a surrogate endpoint, and the abstract reports no histology, body weight or toxicity data.
Ex vivo lymphocyte culture with cobalt chloride and cytogenetic assays · Lymphocytes from donors aged 80 to 91 and 18 to 30
Livagen reduced cobalt-induced chromosomal changes to 3.4 plus or minus 0.6 percent against 4.2 plus or minus 0.7 percent in controls, and shifted sister chromatid exchange toward telomeric heterochromatin.
Evidence scope: Abstract only; cobalt is a laboratory challenge rather than a model of human exposure, and the endpoint is a chromosome surrogate.
Ex vivo lymphocyte culture from patients treated with Livagen and cobalt · Patients with ductal breast cancer
Patients' lymphocytes showed a high density of DNA single-strand breaks, a high frequency of chromosomal abnormalities and increased chromatin condensation, and Livagen with cobalt had a protective effect by all studied parameters.
Evidence scope: Abstract only; the abstract reports only the combined Livagen-and-cobalt treatment, patient numbers are not given, and no clinical outcome was measured.
History and where it stands today
Livagen's literature is small, concentrated in a group of collaborating laboratories in St. Petersburg and Tbilisi, and has never reached a clinical trial.
- 2001Khavinson's group reported synthetic short peptides, including Livagen, that stimulated explants from the organ whose peptide complex supplied the template; Livagen matched liver tissue [1].
- 2002Two 2002 papers reported that Livagen activated ribosomal genes and decondensed pericentromeric heterochromatin in lymphocytes from older donors [4], and that it stabilized cell populations and supported regeneration in organotypic liver culture [5].
- 2003Kost and colleagues found that Livagen inhibited human serum enkephalin-degrading enzymes with an IC50 of 20 micromolar and did not bind mu or delta opioid receptors [11].
- 2004A five-peptide comparison in leukocytes from donors aged 75 to 88 confirmed ribosomal gene activation and added chromosome 1 and 9 pericentromeric decondensation for Livagen [9].
- 2005In rats given Livagen by mouth for two weeks, digestive enzyme activity fell in young animals and rose in old ones, approaching young control levels [12].
- 2007Two papers reported that Livagen opened pericentromeric and telomeric heterochromatin and shifted sister chromatid exchange patterns [10], and that it modified the radiation adaptive response in lymphocytes from donors aged 72 to 86 [13].
- 2017In lymphocyte cultures from patients with ductal breast cancer, Livagen with cobalt ions returned DNA single-strand breaks and chromosomal abnormalities toward normal [14].
- 2020A four-peptide comparison described selective deheterochromatinization of chromosome regions by Livagen and its peers in lymphocytes from donors aged 75 to 88 and a younger comparison group [6].
- 2023Docking of 26 ultrashort peptides put Livagen in the range of known inhibitors at LAT1, LAT2 and PEPT1, while its PEPT2 score was weak and the authors said the PEPT2 data do not allow a reliable assessment [2].
- October 2026As of October 2026, Livagen is not approved for human therapeutic use and no trial of it is registered on ClinicalTrials.gov. Neither the 2026 WADA list nor the NCAA 2026-27 list names it, so WADA's S0 and the NCAA peptide-hormone catch-all apply [7][8]. FDA's Category 2 table of bulk substances with significant safety risks does not list it [15].
How it compares with related peptides
Epithalon is the second member of the same set, matched to subcortical tissue in the founding paper, and it appears beside Livagen in the chromatin comparisons [1][9]. In the 2004 leukocyte study both peptides decondensed chromosome 1 and 9 pericentromeric heterochromatin, while the 2020 comparison found that each peptide opened a different set of regions [6][9]. Livagen's template was liver and Epithalon's was subcortical tissue, which is the tissue-specific logic of the family [1]. See Epithalon for that peptide's literature.
Cortagen is the brain-cortex member, built from a cortical peptide complex, and the 2001 paper pairs it with Livagen as the cortex and liver peptides [1]. Both appear in the 2004 chromatin study, where the peptides differ in which chromosome regions they open; the 2020 comparison found the same selectivity across four peptides [6][9]. Cortagen's founding result is explant growth from brain cortex; Livagen's is growth from liver [1]. The Cortagen page covers the cortical side.
Vilon is the thymus member of the set [1]. In the 2004 comparison Vilon activated ribosomal genes but did not decondense chromosome 1 pericentromeric heterochromatin, which Livagen did, so pericentromeric decondensation is not a generic property of every short peptide [9]. Its template was thymus, and its founding result is explant growth from thymus tissue [1]. See Vilon for the thymus peptide.
Side effects and safety signals
The safety record for Livagen is a laboratory record, because no clinical trial has exposed humans to the peptide.
- No treated human group exists: the human studies in this record are cell and serum experiments, and no clinical trial of Livagen has been published, so there are no reported adverse events, tolerability data or dropouts to review [4][9].
- The human cell studies exposed lymphocytes to the peptide outside the body, a design that can flag chromosome damage but cannot show fever, immune reaction or organ toxicity [4][10].
- The only whole-animal dosing study in the sources reviewed gave the peptide by mouth for two weeks; its abstract reports digestive enzyme shifts and no body weight, histology, blood counts or survival data [12].
- No pharmacokinetic study appears in the sources reviewed, so how much peptide reaches blood or liver after oral use is unmeasured [11][12].
- No genotoxicity, carcinogenicity, reproductive-toxicity or repeat-dose toxicology study of Livagen appears in the sources reviewed, which leaves the standard preclinical safety package unfilled.
- Inhibiting enkephalin-degrading enzymes could prolong opioid peptide signaling in principle, although the serum experiment found no direct binding to mu or delta receptors [11].
- Two chromatin studies tested Livagen together with cobalt ions, and cobalt alone raised chromosomal aberrations in older donors, so the combined-exposure results do not isolate the peptide's effect [10][14].
The future: what's next for Livagen
No Livagen trial is registered. A ClinicalTrials.gov search on October 23, 2026 returned no study, and the sources reviewed contain no sponsor or planned indication. The liver work is the closest thing to a clinical question: organotypic culture examined how liver cell populations hold up, and the rat study asked how digestive enzyme activity shifts with age [5][12].
A first-in-human study would need what the literature lacks: a characterized batch, a measured pharmacokinetic profile and a toxicology package. The 2023 docking paper gives a testable absorption hypothesis by naming LAT1, LAT2 and PEPT1 as candidate transporters [2]. The 2005 finding that intestinal hydrolases do not cleave the peptide makes oral administration the route a pharmacokinetic study would test first, without showing that it delivers active peptide to the liver [12].
The regulatory calendar has no Livagen-specific date. WADA's 2026 list took effect on January 1, 2026 and does not name the peptide, so S0 remains the applicable class until a government approves it for human therapeutic use [7]. The NCAA list covers the 2026-27 academic year and leaves Livagen to the peptide-hormone catch-all [8]. FDA's Category 2 table of bulk substances with significant safety risks does not include it [15].
- Whether Livagen reaches human blood or liver intact after oral or injected use is unmeasured; only docking predictions and test-tube stability data exist [2][12].
- Whether chromatin decondensation in cultured lymphocytes changes the activity of a named gene, and whether that would matter for aging tissue, remains untested [4][6].
- Which serum peptidase Livagen inhibits, and whether prolonging enkephalin signals has a measurable physiological effect, is unresolved [11].
- Whether the liver and digestive-enzyme findings repeat in an independent laboratory, and at what exposure, is unknown [5][12].
- Whether repeated exposure is safe is unknown, since the sources reviewed contain no toxicology or pharmacokinetic study of the peptide.